

Provided by:



## Hematology Oncology Tumor Board Case Conference 2025-2026

**Hematology Oncology Tumor Board Case Conference 2025-2026 - 10/2/2025**

**October 2, 2025**

**8:00 AM - 9:00 AM**

**12-122 Perelman Center South Pavilion**

### **Target Audience**

This program has been designed for INTERNAL MEDICINE - Hematology, INTERNAL MEDICINE - Medical Oncology

### **Series Educational Objectives**

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss treatment options for patients with cancer
- 2 Describe proper evaluation, and as a consultant for patients with unknown diagnosis, but with possible malignancy
- 3 Discuss the role of the medical oncologist in managing patient cancer

### **Accreditation**

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### **Designation of Credit**

**Physicians:** Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses:** This activity is not approved for nursing contact hours

**Pharmacists:** This activity is not approved for pharmacy contact hours

**PAs:** AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*<sup>™</sup> from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of **1.00** Category 1 credits for completing this activity.

**Approved for (PSRM) patient safety/risk management designation**

### **Acknowledgement of Commercial Support\***

None

For more information, please contact  
**Alexa Davis**  
**(215) 662-3681**  
[alexa.davis@uphs.upenn.edu](mailto:alexa.davis@uphs.upenn.edu)

**Check your transcript online at <https://upenn.cloud-cme.com>**

### Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships(RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

| Name of individual    | Individual's role in activity   | Nature of Relationship(s) / Name of Ineligible Company(s)                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------------------|---------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Ursina Teitelbaum, MD | Other Planning Committee Member | Nothing to disclose - 07/10/2025                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Erin Aakhus, MD       | Course Director                 | Nothing to disclose - 09/03/2025                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Sunita D. Nasta, MD   | Co-Director                     | Grant or research support- Genentech   Consulting Fee-ADCT (Relationship has ended)   Grant or research support-ONO pharmaceuticals   Consulting Fee-Genmab   Grant or research support- ATARA   Grant or research support-Cairbou Biosciences   Grant or research support- ASTEX   Grant or research support-Takeda Pharmaceuticals   Grant or research support- AbbVie, Inc.   Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck & Co - 02/11/2025 |
| Kaitlin Demarest, MD  | Faculty                         | Nothing to disclose - 08/13/2025                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected